What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing by Abbott Laboratories is to officially announce and provide their third-quarter 2021 financial results through a furnished press release (Exhibit 99.1).

What types of adjustments does Abbott make to its non-GAAP financial measures?

Abbott's non-GAAP financial measures typically exclude unusual or unpredictable items such as expenses related to acquisitions, restructuring actions, cost reduction initiatives, certain litigation, impairment of assets, and intangible amortization expense.

Why does Abbott provide non-GAAP financial measures?

Abbott provides non-GAAP financial measures to offer investors greater visibility into the company's ongoing business performance, excluding the impact of items that management considers to be unusual or unpredictable. Management uses these measures internally to assess performance.

How should investors interpret Abbott's use of non-GAAP measures?

Abbott advises investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). This means investors should look at both GAAP and non-GAAP figures to get a complete picture.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on October 20, 2021, to announce its third-quarter 2021 financial results. The report primarily serves to furnish a press release detailing these results. Investors should note that while the press release presents both GAAP and non-GAAP financial measures, Abbott emphasizes its non-GAAP figures, which exclude certain items like acquisition-related expenses, restructuring costs, and amortization. These adjustments are presented to offer a clearer view of ongoing operational performance as assessed by management. The company is providing these non-GAAP figures to allow investors to better evaluate the core business performance, excluding unusual or unpredictable factors. While these measures are considered useful by Abbott's management, investors are advised to consider them alongside GAAP measures and not as a substitute. The filing also includes the press release as an exhibit and notes the CFO's signature.

Key Highlights

1Abbott Laboratories announced its Q3 2021 results via an 8-K filing.
2The filing's primary purpose is to furnish the Q3 2021 earnings press release.
3Abbott utilizes both GAAP and non-GAAP financial measures in its reporting.
4Non-GAAP measures exclude items such as acquisition expenses, restructuring costs, and amortization.
5The company believes non-GAAP measures provide greater visibility into ongoing operational performance.
6Investors are encouraged to consider non-GAAP measures in conjunction with, not as a substitute for, GAAP measures.
7The report includes the press release as Exhibit 99.1 and is signed by the CFO.

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 20, 2021)

Summary

Key Highlights

Frequently Asked Questions